BeOne Medicines outlines $5.1B-$5.3B 2025 revenue target amid BRUKINSA momentum and expanding pipeline
Source: SeekingAlpha
2025-11-06 15:17:04 ET
More on BeiGene
- BeOne Medicines AG (ONC) Q3 2025 Earnings Call Transcript
- BeOne Medicines AG 2025 Q3 - Results - Earnings Call Presentation
- BeOne Medicines: Sonrotoclax Could Set Next Stage Of Growth For Hematology Pipeline
- BeiGene Non-GAAP EPADS of $2.65, revenue of $1.4B beats by $40M
- BeiGene Q3 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
BeOne Medicines outlines $5.1B–$5.3B 2025 revenue target amid BRUKINSA momentum and expanding pipeline
BeiGene
NASDAQ: BEIGF
BEIGF Trading
0.0% G/L:
$23.75 Last:
100 Volume:
$23.75 Open:
BEIGF Latest News
BEIGF Stock Data
$38,603,023,416
747,457,849
N/A
299
N/A
Biotechnology & Life Sciences
Healthcare
CH
Basel
